Last updated: February 17, 2026
Overview
NDC 70954-0925 corresponds to Lisocabtagene Maraleucel (Liso-cel), a CAR-T therapy developed for certain hematologic malignancies, including large B-cell lymphoma (LBCL). Approved by the FDA in February 2021 (under accelerated approval) for relapsed or refractory LBCL, it marks a significant advancement in immunotherapy but faces challenges related to cost, market penetration, and competition.
Market Landscape
Indications & Patient Population
- FDA approval: February 2021 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
- Estimated eligible patients globally: roughly 10,000 annually in the U.S. (based on incidence rates and treatment patterns).
Key Competitors
| Product |
Approval Date |
Indications |
Pricing (Launch) |
Market Share (2022) |
| Yescarta (axicabtagene ciloleucel) |
October 2017 |
Relapsed/refractory LBCL |
~$373,000 |
45% |
| Kymriah (tisagenlecleucel) |
August 2017 |
R/R LBCL in adults |
~$475,000 |
35% |
| Breyanzi (lisocabtagene maraleucel) |
February 2021 |
R/R LBCL |
~$410,000 |
15% (2022) |
| Liso-cel (NDC 70954-0925) |
February 2021 |
R/R LBCL |
~$410,000 |
5% (initial) |
Pricing is approximate wholesale acquisition cost (WAC) estimates in the U.S. at launch; actual billed prices vary with discounts, insurance negotiations, and patient assistance programs.
Market Penetration
- Liso-cel initially captured a modest share (<10%) in 12 months.
- Growth depends on safety profiles, manufacturing capacity, and clinician familiarity.
- Its "prefilled, fixed-dose" format aims for streamlined administration, partially differentiating it from competitors.
Regulatory & Commercial Challenges
- Manufacturing delays can restrict supply.
- Logistic complexities of cold chain storage for cell therapies.
- Pricing pressures — insurers and PBMs challenge high upfront costs.
Price Projections and Revenue Potential
Assumptions
- Price remains steady at ~$410,000 per treatment.
- Market penetration increases gradually over five years, reaching approximately 20% share of eligible patients.
- Average treatment cost includes administration and supportive care, with comparator prices in a similar range.
- Reimbursement policies stabilize, minimizing discounts for volume or discounts.
| Year |
Estimated Patients Treated |
Market Share |
Revenue (USD millions) |
Comments |
| 2023 |
1,000 |
5% |
$410 |
Early adoption, manufacturing capacity limits |
| 2024 |
2,000 |
10% |
$820 |
Increasing physician familiarity |
| 2025 |
3,500 |
15% |
$1,435 |
Expanded access, clinical data supports use |
| 2026 |
4,500 |
20% |
$1,845 |
Market stabilization |
| 2027 |
5,500 |
20% |
$1,845 |
Peak sales based on current indication |
Potential Upside
- Expanded indications could increase treated patient numbers.
- Combination therapies or earlier line use might drive higher prices or volumes.
- International approvals could double the market size.
Risks
- Market share plateau due to competition or combination treatment shifts.
- Cost containment initiatives by payers.
- Manufacturing scalability issues leading to supply shortages.
Key Takeaways
- NDC 70954-0925 (Liso-cel) is positioned as a premium-priced immunotherapy targeting relapsed/refractory LBCL.
- Market penetration remains modest but is expected to grow as manufacturing and clinician familiarity improve.
- Price remains stable at approximately $410,000 per treatment; total revenue could reach $1.8 billion annually by 2026 with 20% market share.
- Competition from Yescarta and Kymriah continues, with Breyanzi gradually increasing adoption.
- International expansion and broader indications remain strategic opportunities.
FAQs
1. What factors influence the price of Liso-cel?
Manufacturing complexity, drug efficacy, regulatory environment, competition, payer negotiations, and patient outcomes.
2. How does Liso-cel differ from competitors like Yescarta?
It offers a "pre-made, fixed-dose" format with a potentially safer profile, aiming to streamline manufacturing and administration.
3. What are the barriers to market expansion for Liso-cel?
Manufacturing delays, logistical constraints, reimbursement challenges, and clinician familiarity.
4. How might future pricing trends evolve?
Prices could stabilize or decrease if competition intensifies, or increase if indications expand or combination therapies command premium pricing.
5. What is the forecasted global market opportunity?
Careful estimates project a multi-billion dollar market in the U.S., with international sales potentially adding 50% to 100% depending on approval speed and healthcare infrastructure.
References
- FDA. BLA Approval: Lisocabtagene Maraleucel (liso-cel). 2021.
- IQVIA. Oncology R&D and Market Reports, 2022.
- EvaluatePharma. 2022, Oncology Drugs Market Forecast.
- Company SEC Filings and Investor Presentations. 2022.
- CMS and payor coverage policies. 2022.
[1] U.S. Food and Drug Administration. Lisocabtagene Maraleucel (liso-cel) BLA. 2021.
